FIRST SPECIAL REPORT
The Science and Technology Committee has agreed
to the following Special Report:
THE WORK OF THE SCIENCE AND TECHNOLOGY
COMMITTEE 1997-2000
Introduction
1. The Liaison Committee Report "Shifting
the Balance: Select Committees and the Executive" directed
departmental select committees to provide annual reports, reporting
on progress on past recommendations, difficulties encountered
in Committee work and examples of good practice.[5]
This Special Report is our response. Since we have not produced
such a Report before, this is a Report on our activities in the
whole of this Parliament rather than just the 1999-2000 Session.
2. In this Parliament we have, so far, published
seventeen Reports and nine Special Reports. A list of our Reports
and Government Replies is printed as an Annex to this Special
Report. We draw together here some general conclusions from our
inquiries and other work.
3. Our inquiries have normally resulted in publication
of Reports. However, we have, on occasion, conducted one-off oral
evidence sessions to discuss matters of interest with ministers
or senior officials. We have not had cause to examine any draft
legislation or treaties, nor have we held any confirmation hearings.
4. Since the beginning of the Parliament, the Committee
has undertaken overseas visits to the USA, Canada, Germany and
Helsinki in connection with its inquiries into Engineering and
Physical Sciences Based Innovation and Cancer ResearchA
Fresh Look. We also visited the European Commission in Brussels
to discuss the Fifth Framework, funding for space research and
topics related to current inquiries. The Committee has also travelled
extensively in the UK, particularly in connection with its inquiry
into Cancer ResearchA Fresh Look, when five visits to hospitals
and research centres took place. On one occasion the Committee
took evidence away from Westminster, during a visit to the Generics
Group in Cambridge, in connection with its inquiry into Engineering
and Physical Sciences Based Innovation. On an informal basis,
the Committee has had presentations from, and held discussions
with, various scientific bodies, and also met with science attachés
and delegates from overseas.
The Committee's Remit
5. Under Standing Order No. 152, the Science and
Technology Committee is established to "examine the expenditure,
administration and policy of the Office of Science and Technology".
Thus, we are established as a departmental select committee although
the Office of Science and Technology (OST) is itself just one
part of the Department of Trade and Industry (DTI). But as the
OST has a trans-departmental function, monitoring science and
technology matters in all departments of Government, so we too
have a cross-cutting function. Many of our inquiries, therefore,
extend beyond the executive responsibility of the OST. For instance,
we have been conducting an inquiry into the Scientific Advisory
System for which the head of the OST, the Chief Scientific Adviser,
has responsibility across Government. Two of our inquiries (on
mobile phones and on cancer research) have focussed on matters
largely within the responsibility of the Department of Health,
two (on diabetes and driving, and on climate change) focussed
on matters within the responsibility of the Department of the
Environment, Transport and the Regions and one (on the National
Endowment for Science, Technology and the Arts) within the responsibility
of the Department for Culture, Media and Sport. Other inquiries
have considered matters which fall within the responsibility of
the Ministry of Defence, the Ministry of Agriculture, Fisheries
and Food, and the DTI. We are grateful to other departmental select
committees for their understanding that from time to time we may
scrutinise science matters which are the responsibility of other
Departments. This has had advantages in that it allowed us to
conduct inquiries into scientific aspects of policy in most Government
Departments, but it has limited the extent to which we have built
up a relationship with, and a detailed knowledge of, a single
Department in the way other departmental select committees would
normally do.
6. Because OST is part of the DTI it does not publish
its own Departmental Report and Expenditure Plans. It is for the
Trade and Industry Committee to scrutinise the DTI's Departmental
Report and overall expenditure plans, and the DTI's transition
to resource accounting and budgeting. We have, however, taken
a very close interest in the Science Budget and in DTI policy
on science and innovation. Earlier this year we conducted a series
of evidence sessions on the impact of the 1993 Science White Paper,
Realising our Potential, and are now extending it to cover
the new Science and Innovation White Paper, Excellence and
Opportunity, and the recently announced Science Budget. We
have also resolved to examine each edition of the Forward Look,
which details spending on science, engineering and technology
(SET) research across Government Departments.[6]
7. We have also examined issues relating to industrial
research and development (R&D) and innovation which are a
crucial part of the research activity in the UK. To this end we
have examined, on two occasions, the impact on R&D of the
merger proposals between Glaxo Wellcome and SmithKline Beecham
(which are the two biggest investors in R&D in the UK)[7],
and more recently, on the implications for R&D in the UK of
the creation of Corus plc from British Steel and Hoogovens. Our
extensive inquiry into innovation in Engineering and Physical
Sciences went well beyond Government-funded R&D to look at
the factors important for innovation in industry.[8]
Government Replies
8. Government replies to our Reports have generally
been on time or, by agreement, slightly late, but in a couple
of cases, in which Departments other than OST were involved, the
Government's replies were very late.[9]
In the case of our Report on genetically modified foods, the reply
arrived some six months after the Report was published, barely
in time for a scheduled Westminster Hall debate on the topic and
only after direct complaint to the minister.
9. A further concern is the quality of Government
replies. This is variable. In many cases, the Government has provided
useful and constructive replies but occasionally the standard
falls short of expectations. Indeed, we recently published a Report
commenting on the failure of the Government to provide an adequate
reply to our Fifth Report of Session 1999-2000.[10]
Follow up
10. We have followed up a number of the issues raised
in Government replies to our reports by seeking updates from the
Government on action taken since the reply was published. The
Government's updates are attached as Appendices to this Special
Report. On two occasions we have followed up an inquiry with a
short inquiry into progress, one year later. In 1999, we followed
up our1998 Report into computer compliance with the year 2000
date change.[11]
Our initial inquiry raised a number of concerns about the readiness
of the public and private sectors to cope with the millennium
date change, and our follow up inquiry enabled us to examine and
comment on progress in this critical preparation. Similarly in
1999, we followed up our 1998 Report on British Biotech with a
short inquiry into the Regulation of the Biotechnology Industry.
Use of case studies
11. The Chief Scientific Adviser (CSA) published
guidelines on the use of scientific advice in policy making in
March 1997. Each year, the CSA has reported on progress on implementing
these Guidelines and the OST is currently consulting on a code
of practice for scientific advisory committees. In parallel with
this, we have been conducting an inquiry into the Scientific Advisory
System through a series of case studies. Scientific advice covers
a diverse range of issues, impacting on policy in most areas of
Government. Our case studies have looked at issues as diverse
as genetically modified food and the driving licence rules affecting
people with diabetes. Conducting the inquiry through case studies
has enabled us to consider scientific advice in a range of areas
and identify generic, cross-cutting concerns which apply to best
practice in commissioning, securing and communicating scientific
advice. We will publish our overarching Report on the scientific
advisory system in the new year, taking into account our findings
in our case studies and other material, most notably the report
of the recent BSE inquiry.
Eureka Conference
12. Each year we, together with the Lords Select
Committee on Science and Technology, have contributed Members
to the UK delegation to the EUREKA Inter-Parliamentary Conference.
EUREKA is a network for Europe-wide industrial R&D collaboration.
EUREKA is intended to strengthen European competitiveness, promote
market-driven collaboration in R&D, involve industry and research
institutes across Europe and result in cost effective products,
processes and services. The Inter-Parliamentary Conference holds
discussions and produces a resolution which draws the attention
of the EUREKA Ministerial Conference to particular issues and
developments. Beyond its formal output, participation at the EUREKA
conference has been beneficial to us through the creation of a
networking forum amongst parliamentarians interested in industrial
R&D.
Scrutiny of Code of Practice
13. In conducting an inquiry into the troubled biotechnology
company British Biotech, in 1998, we noted that there were particular
problems for growth companies in this industry, particularly in
terms of disclosure of research results and recommended that there
should be regulation governing the release of information for
the biotechnology industry.[12]
The Government took the view that this was a matter for internal
regulation by the industry; and the BioIndustries Association
(BIA) sought our assistance in developing its Code of Practice.
At the start of the process we were consulted informally on the
sort of thing that the Code should cover; and later, when there
was a working draft, we were asked to comment on it. We reviewed
the Code of Practice and then set up an oral evidence session
with the BIA to discuss it. We subsequently wrote to the BIA with
comments on the draft, most of which were incorporated into the
Code before it was put to BIA members. Our correspondence with
the BIA was published as an Appendix to a short Report.[13]
Multiple witnesses
14. Of the many oral evidence sessions conducted
this Parliament, the most memorable was the occasion on 21 June
2000 when we took oral evidence from some 20 sets of witnesses
in a single session for our inquiry into cancer research. The
idea came from our experiences in the USA where we witnessed members
of the public presenting their evidence to Congressional Committees.
We realised that the main stakeholders in cancer research had
little opportunity to make direct input to the inquiry. The evidence
session required novel and creative practices in terms of taking
oral evidence in public. It also placed unusual demands on us,
our staff and our witnesses and required thorough planning and
organisation. The result of the extra effort was a highly successful,
enlightening and informative session. Many organisations and individualspatients,
carers, health professionals, support groupshad the opportunity
of presenting their views first hand. This session made a real
difference to the inquiry and to the overall tone of the Report.
It changed our perspective on the problem and demonstrated the
urgency of the need to resolve deficiencies in UK Cancer Research.
It also did much to increase the profile of our cancer research
inquiry, which in turn, we believe, increased pressure on the
Government to increase the priority given to cancer research.
Should appropriate circumstances occur again, we would be pleased
to conduct a similar exercise in future inquiries and commend
this approach to other committees.
"Scrutiny"
15. Another notable aspect of our inquiry into cancer
research was the involvement of the BBC "Scrutiny" team
and the resulting TV programme "Fighting Cancer",
which was broadcast shortly after the publication of our report.
There was also a short radio report of our visit to the USA and
Canada. Despite some reservations beforehand, we agreed to be
followed by the Scrutiny team throughout the inquiry. The result
was most satisfactory both in tackling the cancer research issues
and in presenting the various aspects of a complex select committee
inquiry. The additional exposure certainly helped the inquiry.
The interaction with the Scrutiny team was friendly and professional.
The success of this project was to some extent a result of setting
clear ground rules in agreement with the producer in advance of
the project commencing. We regret the BBC's decision not to continue
with the Scrutiny format.
Joint working with the House of Lords Committee
on Science and Technology
16. One of the unique features of the Science and
Technology Committee is that we have a parallel Committee in the
House of Lords. Our relations with our counterparts in the Lords
have been cordial but, at present, cannot be formal. Many of our
interests overlapas can be observed by regular attendance
at the Parliamentary and Scientific Committee of members from
both Committees. Our Chairman has had regular meetings with his
counterpart in the Lords and on one occasion our Chairman and
Clerk were invited to attend a Lords Committee meeting to discuss
future programme, to ensure that the two Committees were not planning
to do the same inquiry at the same time. On 14 November 2000 we
met jointly, although informally, with the Lords Committee and
the former Chief Scientific Adviser to discuss the recent Science
White Paper and other matters.
17. At present, the Lords Select Committee on Science
and Technology has the authority to meet formally with us but
we have no such authority to meet formally with them. After our
informal meeting with the Lords Committee we resolved to seek
the permission of the House to meet formally with them. Our request
is published as our Second Special Report of Session 1999-2000.[14]
We hope that the Leader of the House will table Standing Order
changes shortly. While we would not expect to meet jointly with
the Lords Committee on a regular basis, there are matters of interest
to both committees (for example the appointment of new ministers
and senior officials, new science policy statements and budgets)
where it might be sensible to meet together to avoid duplication
of effort and to improve mutual understanding, as well as to reduce
the demands on ministers.
The Parliamentary Office of Science and Technology
18. The work of the Parliamentary Office of Science
and Technology (POST) has been of major benefit to us. Four of
our Members are also members of the POST Board. Two of our inquiries
have begun with briefing contributed directly by POST. Our Committee
staff benefit greatly from their close, informal liaison with
POST staff. Members of POST staff have come to our private meetings
to provide briefing on complex matters of science and technology
policy and practice. Many areas of public policy are based, in
some way, on scientific evidence but there are those who would
misrepresent scientific evidence for their own political ends.
The impartial analysis and briefing provided by POST has allowed
us, and other parliamentarians, to enter into these debates with
a better understanding of the issues. We note that some other
select committees also use briefing from POST and we would encourage
even wider use of their considerable expertise by other committees.
Science and technology, and POST briefing, can be helpful in understanding
policy issues in most aspects of Governmentas evidenced
by recent POST reports on missile defences, climate change, human
genome research, MOX nuclear fuel, early years learning, biodiversity,
GM crops and so on. We are delighted that the House has recently
resolved to approve the Information Committee's Report recommending
that POST be established on a permanent basis.[15]
Research Infrastructure Funding
19. Throughout this Parliament we have maintained
pressure on the Government to increase Government investment in
research infrastructure. In 1998 we called for a cash injection
of £410-430 million to regenerate infrastructure for university
research.[16]
In response the Government provided £300 million in the Joint
Infrastructure Fund through the 1998 Comprehensive Spending Review,
matched by a contribution by the Wellcome Trust of £300 million.
This funding was later increased to £750 million in total.
In the 2000 Spending Review the Government created the Science
Research Investment Fund which provided a further £1 billion
of new funds for research infrastructure and, critically, appears
to provide for ongoing continuous renewal of research infrastructure
in universities and research council laboratories for the long
term. We welcome the increased funding for the Science Budget,
in the spending reviews of 1998 and, in particular, 2000. We hope,
and believe, that our activities and reports have been an influencing
factor in this success for the academic science base.
5 First Report of the Liaison Committee, Session 1999-2000,
Shifting the Balance: Select Committees and the Executive,
HC 300, paragraphs 51-55. Back
6
Fifth Report, Session 1999-2000, Government Expenditure on
Research and Development: The Forward Look, HC 196-I. Back
7
Third Report, Session 1997-98, Glaxo Wellcome and SmithKline
Beecham: The Merger Proposals, HC 627, and Fourth Report,
Session 1999-2000, Glaxo Wellcome and SmithKline Beecham,
HC 207-I. Back
8
Second Report, Session 1999-2000, Engineering and Physical
Sciences Based Innovation, HC 195-I. Back
9
First Report, Session 1998-99, Scientific Advisory System:
Genetically Modified Food, HC 286-I, published 18 May 1999:
Government Response published as Cm 4527, 9 November 1999. Sixth
Report, Session 1999-2000, Cancer Research - A Fresh Look,
HC 332, published 27 July 2000: Government Response published
as Cm 4928, 17 November 2000. Back
10
Seventh Report, Session 1999-2000, The Government's Expenditure
on Research and Development: The Forward Look-The Government's
Reply, HC 723. Back
11 Second
Report, Session 1997-98, The Year 2000-Computer Compliance,
HC 342-I. First Report, Session 1999-2000, The Year 2000-Computer
Compliance: Follow-Up, HC 37. Back
12 Fifth
Report, Session 1997-98, British Biotech, HC 888. Back
13 Fourth
Report, Session 1998-99, The Regulation of the Biotechnology
Industry, HC 535. Back
14 Second
Special Report, Session 1999-2000, HC 980. Back
15
Official Report, 21 November 2000, col 283. First Report of the
Information Committee, Session 1999-2000, The Future of the
Parliamentary Office of Science and Technology, HC 659, 20
July 2000, paragraph 15. Back
16
First Report, Session 1997-98, The Implications of the Dearing
Report for the Structure and Funding of University Research,
HC 303-I, paragraph 35. Back
|